Robert L. Wolfert
Keine laufenden Positionen mehr
Profil
Robert L.
Wolfert worked as Director-Immunodiagnostics Research at Hybritech, Inc. from 1984 to 1999.
He then worked as Vice President-Research & Development at LPL Technologies, Inc. from 1999 to 2000.
From 2000 to 2010, he served as Chief Scientific Officer & Executive VP at diaDexus, Inc. In 2010, he briefly worked as Chief Scientific Officer & Executive VP at VaxGen, Inc. before returning to diaDexus, Inc. to serve in the same role until 2011.
Wolfert received his undergraduate degree from Cornell University and his doctorate from Tufts University.
Ehemalige bekannte Positionen von Robert L. Wolfert
| Unternehmen | Position | Ende |
|---|---|---|
| DIADEXUS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.10.2011 |
diaDexus, Inc. /Old/
 diaDexus, Inc. /Old/ Medical SpecialtiesHealth Technology diaDexus is a privately held biotechnology company that is focused on the discovery, development and commercialization of novel, patent protected diagnostic products with high clinical value. diaDexus makes a difference by developing innovative products with clinical value to address significant unmet medical needs in the cardiovascular field. | Corporate Officer/Principal | 01.11.2010 |
VaxGen, Inc.
 VaxGen, Inc. BiotechnologyHealth Technology VaxGen, Inc. is a biopharmaceutical company, owns a state-of-the-art biopharmaceutical manufacturing facility that can be used to make cell culture or microbial biologic products. The company has ended all product development activities and sold or otherwise terminated its drug development programs. It is seeking to maximize the value of its remaining tangible and intangible assets through a transaction or series of transactions, including the sale of the manufacturing facility. The company was founded on November 01, 1995 and is headquartered in South San Francisco, CA. | Technik-/Wissenschafts-/F&E-Leiter | 01.11.2010 |
LPL Technologies, Inc.
 LPL Technologies, Inc. Medical/Nursing ServicesHealth Services LPL Technologies, Inc. develops diagnostic blood tests for gynecological cancer. The company was founded in 1996 by Gordon B. Mills and Michael K. Skinner and is headquartered in Cleveland, OH | Technik-/Wissenschafts-/F&E-Leiter | 01.10.2000 |
Hybritech, Inc.
 Hybritech, Inc. Miscellaneous Commercial ServicesCommercial Services Hybritech, Inc. provides prostate diagnostic testing services. The company is headquartered in San Diego, CA. | Corporate Officer/Principal | 01.04.1999 |
Ausbildung von Robert L. Wolfert
| Cornell University | Undergraduate Degree |
| Tufts University | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 5 |
|---|---|
diaDexus, Inc. /Old/
diaDexus, Inc. /Old/ Medical SpecialtiesHealth Technology diaDexus is a privately held biotechnology company that is focused on the discovery, development and commercialization of novel, patent protected diagnostic products with high clinical value. diaDexus makes a difference by developing innovative products with clinical value to address significant unmet medical needs in the cardiovascular field. | Health Technology |
LPL Technologies, Inc.
LPL Technologies, Inc. Medical/Nursing ServicesHealth Services LPL Technologies, Inc. develops diagnostic blood tests for gynecological cancer. The company was founded in 1996 by Gordon B. Mills and Michael K. Skinner and is headquartered in Cleveland, OH | Health Services |
Hybritech, Inc.
Hybritech, Inc. Miscellaneous Commercial ServicesCommercial Services Hybritech, Inc. provides prostate diagnostic testing services. The company is headquartered in San Diego, CA. | Commercial Services |
VaxGen, Inc.
VaxGen, Inc. BiotechnologyHealth Technology VaxGen, Inc. is a biopharmaceutical company, owns a state-of-the-art biopharmaceutical manufacturing facility that can be used to make cell culture or microbial biologic products. The company has ended all product development activities and sold or otherwise terminated its drug development programs. It is seeking to maximize the value of its remaining tangible and intangible assets through a transaction or series of transactions, including the sale of the manufacturing facility. The company was founded on November 01, 1995 and is headquartered in South San Francisco, CA. | Health Technology |
Diadexus, Inc.
 Diadexus, Inc. BiotechnologyHealth Technology Diadexus, Inc. engages in the research, development, and commercialization of pharmaceutical products. Its portfolio intends to treat cardiovascular diseases. The company was founded on November 27, 1995 and is headquartered in South San Francisco, CA. | Health Technology |
